Stocks Health care MRMD
OTC · Health careMarimed Inc. (MRMD)
Marimed Inc. brought in $163.8M of revenue over the twelve months to June 30, 2026, up 4.5% from a year earlier. It posted a net loss of $15M. Operating cash flow minus capital spending left $6.5M of free cash flow in fiscal 2025. At June 30, 2026 it held $8.4M in cash against $82.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch MRMD in 60 secondsWhat Marimed Inc. does
Marimed Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker MRMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $159.8M | -$14.5M | -$0.04 | $6.5M |
| 2024 | $157.7M | -$12.5M | -$0.03 | -$5.2M |
| 2023 | $148.6M | -$16M | -$0.04 | -$12.2M |
| 2022 | $134M | $13.5M | $0.04 | -$4.8M |
| 2021 | $121.5M | $7.2M | $0.02 | $18M |
| 2020 | $50.9M | $2.1M | $0.01 | -$1.3M |
Full financial statements: income, balance sheet and cash flow
Where MRMD ranks in Health care
Latest SEC filings
What Marimed Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Other event 8-K
- September 22, 2026Proxy statement DEF 14A
- September 11, 2026Preliminary proxy statement PRE 14A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 6.1% to $41.9M versus the same quarter last year; diluted EPS -$0.01 versus $0.00.
- August 12, 2026
- June 8, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 4.2% to $39.5M versus the same quarter last year; diluted EPS -$0.01 versus -$0.01.
- May 13, 2026
- April 23, 2026
- April 23, 2026Proxy statement DEF 14A
What is MRMD worth? A DCF from its reported cash flow
Insider trades
What the people running Marimed Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 13 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Shaw TimothyChief Operating Officer | Exercised options | 65,000 | - |
| September 1, 2026 | Shaw TimothyChief Operating Officer | Shares withheld for tax | 22,523 | $1.8K |
| July 15, 2026 | Gildea Edward JDirector | Exercised options | 192,308 | - |
| July 15, 2026 | Allen David RDirector | Exercised options | 192,308 | - |
| July 15, 2026 | Selhub Eva M.D.Director | Exercised options | 173,077 | - |
| July 15, 2026 | Pinho MarioChief Financial Officer | Exercised options | 88,276 | - |
| July 15, 2026 | Pinho MarioChief Financial Officer | Shares withheld for tax | 30,589 | $2K |
| July 15, 2026 | Crandall RyanChief Commercial Officer | Exercised options | 32,813 | - |
| July 15, 2026 | Crandall RyanChief Commercial Officer | Shares withheld for tax | 11,370 | $752.7 |
| July 15, 2026 | Shaw TimothyChief Operating Officer | Exercised options | 42,656 | - |
| July 15, 2026 | Shaw TimothyChief Operating Officer | Shares withheld for tax | 14,781 | $978.5 |
| July 15, 2026 | Levine Jon RPresident and CEO, Director, 10% owner | Exercised options | 30,625 | - |
| July 15, 2026 | Levine Jon RPresident and CEO, Director, 10% owner | Shares withheld for tax | 10,612 | $702.5 |
| June 15, 2026 | Crandall RyanChief Commercial Officer | Exercised options | 250,000 | - |
| June 15, 2026 | Crandall RyanChief Commercial Officer | Shares withheld for tax | 86,626 | $6K |
Who owns MRMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
7 insiders reported holding 34,919,365 shares in total, about $2.5M at the last price.
| Holder | Shares |
|---|---|
| Levine Jon RPresident and CEO, Director, 10% owner | 21,358,631 |
| Shaw TimothyChief Operating Officer | 9,454,600 |
| Gildea Edward JDirector | 1,172,516 |
| Crandall RyanChief Commercial Officer | 1,124,246 |
| Allen David RDirector | 743,452 |
| Selhub Eva M.D.Director | 730,748 |
| Pinho MarioChief Financial Officer | 335,172 |
Questions about MRMD
What does Marimed Inc. do?
Marimed Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker MRMD.
Is Marimed Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $15M on revenue of $163.8M.
How much revenue does Marimed Inc. make?
Over the twelve months to June 30, 2026 Marimed Inc. reported revenue of $163.8M. That is 4.5% more than a year earlier.
When did Marimed Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 23, 2026.
Similar companies
Compare MRMD with
Follow MRMD
Get an email when Marimed Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MRMD: get an email when it filesWhere the numbers come from
Financial figures are the values Marimed Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.